Immunogenicity of COVID ‐19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapy
Summary: Immune responses to primary COVID‐19 vaccination were investigated in 58 patients with follicular lymphoma (FL) as part of the PETReA trial of frontline therapy (EudraCT 2016–004010‐10). COVID‐19 vaccines (BNT162b2 or ChAdOx1) were administered before, during or after cytoreductive treatmen...
Principais autores: | Lim, YJ, Ward, V, Brown, A, Phillips, E, Kronsteiner, B, Malone, T, Jennings, D, Healy, S, Longet, S, James, T, Thomson, P, Farrell, L, Oates, M, Jackson, R, Morrison, A, Burns, M, Carroll, M, Klenerman, P, Turtle, L, Naisbitt, D, Rhodes, M, Robinson, K, Gatto, S, Young, M, Eyre, TA, Eyre, DW, Dunachie, S, Barnes, E |
---|---|
Formato: | Journal article |
Idioma: | English |
Publicado em: |
Wiley
2024
|
Registros relacionados
-
P1095: COVID-19 VACCINE RESPONSES IN FOLLICULAR LYMPHOMA: DETERMINANTS OF HUMORAL AND CELLULAR IMMUNITY IN THE PETREA TRIAL OF FRONTLINE CHEMOIMMUNOTHERAPY
por: Yeong Jer Lim, et al.
Publicado em: (2023-08-01) -
Interim Positron Emission Tomography During Frontline Chemoimmunotherapy for Follicular Lymphoma
por: Reid W. Merryman, et al.
Publicado em: (2023-02-01) -
Follicular Lymphoma in Chile in the Adult Public Cancer Program: The Impact of Chemoimmunotherapy
por: María Elena Cabrera, et al.
Publicado em: (2024-09-01) -
Venous thromboembolism in primary central nervous system lymphoma during frontline chemoimmunotherapy
por: Hiu Lam Agnes Yuen, et al.
Publicado em: (2020-08-01) -
Symptomatic Follicular Lymphoma: Complete Remission After Chemoimmunotherapy with Bendamustine–Rituximab
por: Wulyo Rajabto, et al.
Publicado em: (2024-04-01)